FMP
Oyster Point Pharma, Inc.
OYST
NASDAQ
Inactive Equity
As of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc. Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.
11.17 USD
0 (0%)
About
ceo
Dr. Jeffrey Nau
sector
Healthcare
industry
Biotechnology
website
https://www.oysterpointrx.com
exchange
NASDAQ
Description
As of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc. Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.
CIK
0001720725
ISIN
US69242L1061
CUSIP
69242L106
Address
202 Carnegie Ctr Ste 109
Phone
16093829032
Country
US
Employee
303
IPO Date
Oct 31, 2019
Summary
CIK
0001720725
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
69242L106
ISIN
US69242L1061
Country
US
Price
11.17
Beta
0
Volume Avg.
417.56k
Market Cap
0
Shares
-
52-Week
3.46-13.45
DCF
18.58
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
0
P/B
-
Website
https://www.oysterpointrx.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest OYST News
It looks like there's no news available.
